

References

1. Sun T. 2011. Clinical Application, Case 16, Ch 6. In *Flow Cytometry and Immunohistochemistry for Hematologic Neoplasms*, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins.

Chronic Lymphocytic Leukemia (CLL)



testing at ARUP Laboratories



aruplab.com

ARUP LABORATORIES
500 Chipeta Way
Salt Lake City, UT 84108-1221
Phone: 800-522-2787
Fax: 801-583-2712

keyword: CLL


A nonprofit enterprise of the University of Utah and its Department of Pathology

© 2021 ARUP Laboratories
BD-CS-039, Rev 3, November 2021



aruplab.com/testing/CLL

Chronic lymphocytic leukemia (CLL) is characterized by small lymphocytes in the bone marrow, blood, and lymphoid tissues. CLL is the most common form of leukemia in adults in the U.S. and represents **40% of all adult leukemias in Western countries.**¹



Cytogenetic, molecular, and flow cytometric testing play an important role in prognostication for CLL patients.

ARUP TEST CODE AND NAME		RECOMMENDED USE
2012844	CD200 by Immunohistochemistry	Primarily aids in the distinction between CLL/SLL and mantle-cell lymphoma where CD200 is usually positive in CLL/SLL and negative in mantle cell lymphoma; CD200 is also positive in other B-cell lymphoproliferative disorders.
2002290	Chromosome Analysis, Leukemic Blood	For diagnosis, prognosis, and monitoring of hematopoietic neoplasms.
2002292	Chromosome Analysis, Bone Marrow	For diagnosis, prognosis, and monitoring of hematopoietic neoplasms.
2002295	Chromosome FISH, CLL Panel	Alternate test to detect prognostically important genomic abnormalities in CLL.
3003142	Chronic Lymphocytic Leukemia Minimum Residual Disease by Flow Cytometry	Limited phenotyping panel, using peripheral blood or bone marrow, to enumerate and characterize chronic lymphocytic leukemia cells (CD5+ monoclonal B-cells) in patients with previously established diagnosis of CLL.
3001858	Chronic Lymphocytic Leukemia Mutation Panel by Next Generation Sequencing	Assesses for single gene mutations, including substitutions and smaller insertions and deletions that may have implications for prognosis or clinical management in patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders.
2006325	Cytogenomic SNP Microarray - Oncology	Monitors diseases progression and response to therapy. Preferred test on fresh specimens at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving: <ul style="list-style-type: none"> • Loss/gain of DNA • Loss of heterozygosity (LOH)
0040227	IGHV Mutation Analysis by Sequencing	Determines risk group in newly diagnosed CLL.
3001780	Leukemia/Lymphoma Phenotyping Evaluation by Flow Cytometry	Aids in evaluation of hematopoietic neoplasms (i.e., leukemia, lymphoma).
0049250	p53 with Interpretation by Immunohistochemistry	Determine risk group for newly diagnosed CLL.

